Literature DB >> 20356563

Structural binding evidence of the trypanocidal drugs berenil and pentacarinate active principles to a serine protease model.

Cecília Steinberg Perilo1, Márcio Tadeu Pereira, Marcelo Matos Santoro, Ronaldo Alves Pinto Nagem.   

Abstract

Bovine trypsin is a model system for the serine protease class of enzymes, which is an important target for contemporary medicinal chemistry. Some structural and thermodynamic reports are available on its interaction with benzamidine-based compounds but no structural information is available so far on its binding modes to the active principles of the trypanocidal drugs Pentacarinate (pentamidine) and Berenil (diminazene). The crystallographic structures of bovine beta-trypsin in complex with the ligands were determined to a resolution of 1.57 A (diminazene) and 1.70 A (diminazene and pentamidine). The second benzamidine moieties in these inhibitors are bound to the enzyme in different hot spots and only few hydrogen bonds mediate these interactions. Thermodynamic parameters for the association of pentamidine with beta-trypsin reveal that this inhibitor has about 1.3-fold lower affinity than diminazene. Moreover its binding mode resembles other benzamidine-based compounds that assess the aryl binding pocket of the enzyme; however, with almost 2.5-fold higher affinity. This is the first structural evidence of the binding of Berenil and Pentacarinate active principles trypanocidal drugs to serine proteases. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20356563     DOI: 10.1016/j.ijbiomac.2010.03.006

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  5 in total

1.  Evaluation of docking performance in a blinded virtual screening of fragment-like trypsin inhibitors.

Authors:  Georgiana Surpateanu; Bogdan I Iorga
Journal:  J Comput Aided Mol Des       Date:  2011-12-17       Impact factor: 3.686

2.  X-ray evidence of a native state with increased compactness populated by tryptophan-less B. licheniformis β-lactamase.

Authors:  Valeria A Risso; Juan P Acierno; Stefano Capaldi; Hugo L Monaco; Mario R Ermácora
Journal:  Protein Sci       Date:  2012-05-31       Impact factor: 6.725

3.  Diminazene aceturate: an antibacterial agent for Shiga-toxin-producing Escherichia coli O157:H7.

Authors:  Si-Ying Wu; Gil-Yong Park; So-Hee Kim; John Hulme; Seong Soo A An
Journal:  Drug Des Devel Ther       Date:  2016-10-14       Impact factor: 4.162

4.  Small molecule inhibitors of mesotrypsin from a structure-based docking screen.

Authors:  Olumide Kayode; Zunnan Huang; Alexei S Soares; Thomas R Caulfield; Zigang Dong; Ann M Bode; Evette S Radisky
Journal:  PLoS One       Date:  2017-05-02       Impact factor: 3.240

5.  Drug reformulation for a neglected disease. The NANOHAT project to develop a safer more effective sleeping sickness drug.

Authors:  Lisa Sanderson; Marcelo da Silva; Gayathri N Sekhar; Rachel C Brown; Hollie Burrell-Saward; Mehmet Fidanboylu; Bo Liu; Lea Ann Dailey; Cécile A Dreiss; Chris Lorenz; Mark Christie; Shanta J Persaud; Vanessa Yardley; Simon L Croft; Margarita Valero; Sarah A Thomas
Journal:  PLoS Negl Trop Dis       Date:  2021-04-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.